Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects

This study has been completed.
Information provided by:
Cubist Pharmaceuticals Identifier:
First received: August 24, 2005
Last updated: March 6, 2009
Last verified: March 2009

ABD101684 serves as an extension to Study SB-767905/008 and offers continued access to blinded investigational product to subjects who have completed the original study.

Condition Intervention Phase
Bowel Dysfunction
Drug: alvimopan
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Double-Blind, Placebo-Controlled, Multicenter Phase IIb Extension Study to Evaluate the Safety and Efficacy of Multiple Alvimopan Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects

Resource links provided by NLM:

Further study details as provided by Cubist Pharmaceuticals:

Primary Outcome Measures:
  • Incidence of reported adverse events, including serious adverse events

Secondary Outcome Measures:
  • Incidence of treatment-limiting toxicities, changes in pain intensity, patient satisfaction, health outcome measures

Estimated Enrollment: 100
Study Start Date: September 2004
Intervention Details:
    Drug: alvimopan
    Other Name: alvimopan

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Completed GSK sponsored alvimopan (opioid-induced bowel dysfunction) OBD study for subjects with cancer-related pain, e.g. SB-767905/008.
  • Taking full agonist opioid therapy for cancer related pain.
  • Met entry criteria of OBD in original study and per investigator continues to require therapy for management of OBD.
  • Capable of completing paper questionnaires at the study visits.

Exclusion Criteria:

  • Unable to eat or drink.
  • Taking opioids for management of drug addiction.
  • Unable to use only rescue laxatives provided.
  • Inappropriately managed severe constipation that puts subject at risk of complications.
  • Has gastrointestinal (GI) or pelvic disorder known to affect bowel transit.
  • Concomitant medication(s), medical condition, or clinically significant laboratory abnormality that could jeopardize subject and also contraindicate study participation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00135577

  Hide Study Locations
United States, California
GSK Investigational Site
Duarte, California, United States, 91010
GSK Investigational Site
Fountain Valley, California, United States, 92708
GSK Investigational Site
La Verne, California, United States, 91750
GSK Investigational Site
Sacramento, California, United States, 95819
GSK Investigational Site
San Diego, California, United States, 92103
United States, Florida
GSK Investigational Site
New Port Richey, Florida, United States, 34652
GSK Investigational Site
Tampa, Florida, United States, 33612-9497
United States, Iowa
GSK Investigational Site
West Des Moines, Iowa, United States, 50265
United States, Massachusetts
GSK Investigational Site
Boston, Massachusetts, United States, 02215
GSK Investigational Site
Worcester, Massachusetts, United States, 01608
United States, Missouri
GSK Investigational Site
St. Louis, Missouri, United States, 63141
United States, North Carolina
GSK Investigational Site
Durham, North Carolina, United States, 27710
GSK Investigational Site
Hendersonville, North Carolina, United States, 28793
United States, Washington
GSK Investigational Site
Tacoma, Washington, United States, 98405
Canada, Manitoba
GSK Investigational Site
Winnipeg, Manitoba, Canada, R3A 1R9
Canada, Newfoundland and Labrador
GSK Investigational Site
Saint John's, Newfoundland and Labrador, Canada, A1B 3V6
Canada, Ontario
GSK Investigational Site
Kitchener, Ontario, Canada, N2G 1G3
GSK Investigational Site
Sudbury, Ontario, Canada, P3E 5J1
Canada, Quebec
GSK Investigational Site
Bonaventure, Quebec, Canada, G0C 1E0
GSK Investigational Site
Chandler, Quebec, Canada, G0C 1K0
GSK Investigational Site
Sherbrooke, Quebec, Canada, J1H 1Z1
GSK Investigational Site
Helsinki, Finland, 00029
GSK Investigational Site
Bordeaux Cedex, France, 33076
GSK Investigational Site
Strasbourg, France, 67000
GSK Investigational Site
Vandoeuvre-Les-Nancy, France, 54511
GSK Investigational Site
Villejuif Cedex, France, 94805
Hong Kong
GSK Investigational Site
Kwun Tong, Hong Kong
New Zealand
GSK Investigational Site
Wellington, New Zealand, 6002
GSK Investigational Site
Lahore, Pakistan, 54600
GSK Investigational Site
Lima, Peru, Lima 34
GSK Investigational Site
Bialystok, Poland, 15-540
GSK Investigational Site
Lublin, Poland, 20-090
GSK Investigational Site
Olsztyn, Poland, 10-228
GSK Investigational Site
Otwock, Poland, 05-400
GSK Investigational Site
Poznan, Poland, 60-569
GSK Investigational Site
Lisboa, Portugal, 1070
GSK Investigational Site
Lisboa, Portugal, 1800
Russian Federation
GSK Investigational Site
Moscow, Russian Federation, 117216
GSK Investigational Site
Alcorcon, Spain, 28922
United Kingdom
GSK Investigational Site
Nottingham, United Kingdom, NG5 1PB
Sponsors and Collaborators
Cubist Pharmaceuticals
Study Director: GSK Clinical Trials, MD GlaxoSmithKline
  More Information

No publications provided

Responsible Party: Study Director, GSK Identifier: NCT00135577     History of Changes
Other Study ID Numbers: ABD101684
Study First Received: August 24, 2005
Last Updated: March 6, 2009
Health Authority: United States: Food and Drug Administration

Keywords provided by Cubist Pharmaceuticals:
opioid-induced bowel dysfunction

Additional relevant MeSH terms:
Gastrointestinal Diseases
Intestinal Diseases
Digestive System Diseases
Gastrointestinal Agents
Pharmacologic Actions
Therapeutic Uses processed this record on November 27, 2014